S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
Novo Nordisk Arms Wegovy to Be a Triple Threat
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
When Will the Next Bull Market Be?
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
Novo Nordisk Arms Wegovy to Be a Triple Threat
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
When Will the Next Bull Market Be?
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
Novo Nordisk Arms Wegovy to Be a Triple Threat
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
When Will the Next Bull Market Be?
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
Novo Nordisk Arms Wegovy to Be a Triple Threat
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
When Will the Next Bull Market Be?
NASDAQ:NGNE

Neurogene (NGNE) Stock Price, News & Analysis

$37.43
-2.27 (-5.72%)
(As of 04/15/2024 ET)
Today's Range
$36.25
$39.71
50-Day Range
$29.14
$50.90
52-Week Range
$12.20
$53.00
Volume
88,805 shs
Average Volume
131,483 shs
Market Capitalization
$480.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$49.00

Neurogene MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
30.9% Upside
$49.00 Price Target
Short Interest
Bearish
7.87% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.39mentions of Neurogene in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($6.77) to ($3.74) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.18 out of 5 stars

Medical Sector

884th out of 929 stocks

Pharmaceutical Preparations Industry

409th out of 429 stocks

NGNE stock logo

About Neurogene Stock (NASDAQ:NGNE)

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. The company was founded in 2018 and is headquartered in New York, New York.

NGNE Stock Price History

NGNE Stock News Headlines

Neurogene (NASDAQ:NGNE) Shares Up 3.3%
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Akero Therapeutics, Inc.
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
See More Headlines
Receive NGNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurogene and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/15/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NGNE
Previous Symbol
NASDAQ:NGNE
Employees
91
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$49.00
High Stock Price Target
$61.00
Low Stock Price Target
$31.00
Potential Upside/Downside
+28.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-36,320,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$14.51 per share

Miscellaneous

Free Float
12,650,000
Market Cap
$489.71 million
Optionable
No Data
Beta
1.26
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Rachel L. McMinn Ph.D. (Age 51)
    Founder, CEO & Director
  • Ms. Christine Mikail Cvijic J.D. (Age 46)
    President, CFO & Secretary
  • Mr. Arvind Sreedharan
    Senior Vice President of Business Operations
  • Dr. Stuart Cobb Ph.D.
    Chief Scientific Officer
  • Ms. Donna M. Cochener-Metcalfe J.D. (Age 48)
    Senior Vice President & General Counsel
  • Dr. Effie Albanis M.D.
    Senior Vice President of Early Clinical & Translational Research
  • Dr. Andrew E. Mulberg CPI
    FAAP, M.D., Senior Vice President of Regulatory Affairs, Quality Assurance & Quality Control
  • Mr. Ricardo Jimenez
    Senior Vice President of Technical Operations
  • Dr. Albena Patroneva M.B.A. (Age 59)
    M.D., Senior Vice President of Clinical Development
  • Dr. Julie Jordan M.D. (Age 51)
    Chief Medical Officer

NGNE Stock Analysis - Frequently Asked Questions

Should I buy or sell Neurogene stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neurogene in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NGNE shares.
View NGNE analyst ratings
or view top-rated stocks.

What is Neurogene's stock price target for 2024?

4 Wall Street research analysts have issued 1-year target prices for Neurogene's shares. Their NGNE share price targets range from $31.00 to $61.00. On average, they anticipate the company's share price to reach $49.00 in the next twelve months. This suggests a possible upside of 30.9% from the stock's current price.
View analysts price targets for NGNE
or view top-rated stocks among Wall Street analysts.

How have NGNE shares performed in 2024?

Neurogene's stock was trading at $19.38 at the beginning of the year. Since then, NGNE stock has increased by 93.1% and is now trading at $37.43.
View the best growth stocks for 2024 here
.

Are investors shorting Neurogene?

Neurogene saw a increase in short interest in March. As of March 31st, there was short interest totaling 906,000 shares, an increase of 130.4% from the March 15th total of 393,200 shares. Based on an average daily volume of 135,600 shares, the short-interest ratio is presently 6.7 days. Approximately 7.9% of the shares of the stock are short sold.
View Neurogene's Short Interest
.

When is Neurogene's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our NGNE earnings forecast
.

How do I buy shares of Neurogene?

Shares of NGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NGNE) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners